Literature DB >> 28125317

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world.

Yadong A Cui1, Harshila Patel2, William M O'Neil2, Se Li1, Patricia Saddier1.   

Abstract

S. pneumoniae infection remains a serious public health concern despite the availability of vaccines covering up to 23 of more than 94 known serotypes. The purpose of the present study was to monitor recent serotype distribution data. PubMed, EMBASE, Cochrane Reviews and Ingenta databases were searched. Serotype data covering invasive pneumococcal disease (IPD) and non-IPD were extracted from articles published from March 2014 to March 2015. Fifty-nine studies presented pneumococcal serotype prevalence by specific age categories. Most prevalent serotypes not covered by pneumococcal conjugate vaccines (PCV) were as follows: 15B, 22F, 15A, 23A among children under the age of 7 y with IPD; among adults with IPD: 22F, 11A, 10A, 38 in the 65 y and older age group; 12F, 9N, 8 in the 50-64 year-old age group and 12F, 8, 6C, 16F in the 15-59 age group. Geographic variations in serotype distribution highlight the importance of monitoring evolving pneumococcal serotype prevalence after pneumococcal vaccine implementation.

Entities:  

Keywords:  Streptococcus pneumoniae; invasive pneumococcal disease; pneumococcal carriage; pneumococcal conjugate vaccines; pneumococcal serotypes

Mesh:

Year:  2017        PMID: 28125317      PMCID: PMC5489298          DOI: 10.1080/21645515.2016.1277300

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  61 in total

1.  Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.

Authors:  Philippe De Wals; Brigitte Lefebvre; France Markowski; Geneviève Deceuninck; Fannie Defay; Monique Douville-Fradet; Monique Landry
Journal:  Vaccine       Date:  2014-01-31       Impact factor: 3.641

2.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

3.  Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009.

Authors:  Jonathan M Wortham; Elizabeth R Zell; Tracy Pondo; Lee H Harrison; William Schaffner; Ruth Lynfield; Ann Thomas; Arthur Reingold; Nancy M Bennett; Susan Petit; Deborah Aragon; Joseph Bareta; Billie A Juni; Monica M Farley; Bernard Beall; Matthew R Moore
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

4.  Trends in asymptomatic nasopharyngeal colonization with streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada.

Authors:  Leah J Ricketson; Melissa L Wood; Otto G Vanderkooi; Judy C MacDonald; Irene E Martin; Walter H B Demczuk; James D Kellner
Journal:  Pediatr Infect Dis J       Date:  2014-07       Impact factor: 2.129

5.  Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.

Authors:  Zitta Barrella Harboe; Tine Dalby; Daniel M Weinberger; Thomas Benfield; Kåre Mølbak; Hans Christian Slotved; Camilla H Suppli; Helle Bossen Konradsen; Palle Valentiner-Branth
Journal:  Clin Infect Dis       Date:  2014-07-16       Impact factor: 9.079

6.  Bacterial spectrum of spontaneously ruptured otitis media in the era of pneumococcal conjugate vaccination in Germany.

Authors:  Mark van der Linden; Matthias Imöhl; Andreas Busse; Markus Rose; Dieter Adam
Journal:  Eur J Pediatr       Date:  2014-08-30       Impact factor: 3.183

7.  Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).

Authors:  Helio S Sader; Rodrigo E Mendes; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

8.  Nineteen-years of pneumococcal invasive disease surveillance in a children's hospital in Mendoza, Argentina.

Authors:  Héctor José Abate; Andrea Falaschi; Laura Balbi; Beatriz García
Journal:  Arch Argent Pediatr       Date:  2014-08       Impact factor: 0.694

Review 9.  Pneumococcal serotype evolution in Western Europe.

Authors:  Myint Tin Tin Htar; Dina Christopoulou; Heinz-Josef Schmitt
Journal:  BMC Infect Dis       Date:  2015-10-14       Impact factor: 3.090

10.  The role of influenza and parainfluenza infections in nasopharyngeal pneumococcal acquisition among young children.

Authors:  Carlos G Grijalva; Marie R Griffin; Kathryn M Edwards; John V Williams; Ana I Gil; Hector Verastegui; Stella M Hartinger; Jorge E Vidal; Keith P Klugman; Claudio F Lanata
Journal:  Clin Infect Dis       Date:  2014-03-12       Impact factor: 9.079

View more
  8 in total

1.  A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.

Authors:  David Fitz-Patrick; Mariano Young; Daniel A Scott; Ingrid L Scully; Gary Baugher; Yahong Peng; Kathrin U Jansen; William Gruber; Wendy Watson
Journal:  Hum Vaccin Immunother       Date:  2021-02-05       Impact factor: 3.452

2.  Hospital-based sentinel surveillance for Streptococcus pneumoniae and other invasive bacterial diseases in India (HBSSPIBD): design and methodology.

Authors:  Prabu Rajkumar; Sukumar Bharathy; C P Girish Kumar; Balaji Veeraraghavan; Valsan Verghese; Nivedita Gupta; Boopathi Kangusamy; Muthusamy Ravi; Yuvaraj Jayaraman
Journal:  BMJ Open       Date:  2020-04-08       Impact factor: 2.692

3.  Streptococcus pneumoniae serotype 22F infection in respiratory syncytial virus infected neonatal lambs enhances morbidity.

Authors:  Sarhad Alnajjar; Panchan Sitthicharoenchai; Jack Gallup; Mark Ackermann; David Verhoeven
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

4.  Streptococcus pneumoniae Serotypes Associated with Death, South Africa, 2012-2018.

Authors:  Annelies Müller; Jackie Kleynhans; Linda de Gouveia; Susan Meiring; Cheryl Cohen; Lucy Jane Hathaway; Anne von Gottberg
Journal:  Emerg Infect Dis       Date:  2022-01       Impact factor: 6.883

5.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in the Philippines, 2012-2018.

Authors:  Sonia B Sia; Marietta L Lagrada; June M Gayeta; Melissa Ana L Masim; Jaywardeen P Abad; Mariane A Magbanua; Ferissa B Ablola
Journal:  Western Pac Surveill Response J       Date:  2021-11-29

6.  Pneumococcal nasopharyngeal carriage in children under 5 years of age at an outpatient healthcare facility in Novi Sad, Serbia during the COVID-19 pandemic.

Authors:  Vladimir Petrović; Biljana Milosavljević; Milan Djilas; Miloš Marković; Vladimir Vuković; Ilija Andrijević; Mioljub Ristić
Journal:  IJID Reg       Date:  2022-07-07

7.  Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.

Authors:  Ana Lucia Andrade; Eliane T Afonso; Ruth Minamisava; Ana Luiza Bierrenbach; Elier B Cristo; Otaliba L Morais-Neto; Gabriela M Policena; Carla M A S Domingues; Cristiana M Toscano
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

8.  Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.

Authors:  Donald Hurley; Carl Griffin; Mariano Young; Daniel A Scott; Michael W Pride; Ingrid L Scully; John Ginis; Joseph Severs; Kathrin U Jansen; William C Gruber; Wendy Watson
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.